GenScript and Immunologix team on Ab discovery to trial platform

- Last updated on GMT

Related tags: Contract research organization

US CRO GenScript and therapeutic antibody (Ab) specialist Immunologix have teamed up to offer an integrated development platform.

The deal, which will combined Immunologix’ Ab production capabilities with GenScript’s range of early development and scale-up services, will focus on providing drug firms with everything from discovery to trial stage support.

Nick Yan, GenScript VP, said: “Jointly, we can offer one-stop solutions and complete portfolios to our clients for all their needs in human therapeutic antibody from target identification to clinic candidates cost-effectively and time-efficiently​.”

The global antibody therapeutics market, worth around $27.4bn in 2008, will generate revenue of some $67.6bn by 2015 according to recent analysis by GBI Research.

This growth is likely to attract the attention of a drug industry keen to maintain profitability and, in turn, generate business for the contract research organisations that serve this highly specialised part of the drug industry.

Related news

Related products

show more

QPS: Global Custom-Built Research Services

QPS: Global Custom-Built Research Services

QPS | 16-Dec-2019 | Product Brochure

Performing complex studies in special populations with remarkable agility. Clinical research just got better with QPS’ Custom-Built Research Services....

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us

Products

View more

Webinars